Authors : Sujal Patel; Darshan Patel; Anshu Patel; Prachi Patel; Shikha Limbachiya; Dhiren Chaudhry

Volume/Issue : Volume 11 - 2026, Issue 2 - February

Google Scholar : https://tinyurl.com/mvwhrpaw

DOI : https://doi.org/10.38124/ijisrt/26feb799

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : "Across the globe, tuberculosis (TB) is still a severe public health challenge. This is especially true in developing nations that are experiencing an upward trend in both the number of infections and resistance to treatments.". The present study aimed to evaluate drug utilization patterns among tuberculosis patients attending the District TB Center, Mehsana. A retrospective observational analysis was conducted to assess prescribing trends, rationality of therapy, adherence to national treatment guidelines, and the prevalence of drug-resistant cases. Data were collected from patient treatment records, including demographic characteristics, diagnostic methods, type of TB (pulmonary or extrapulmonary), and prescribed anti-tubercular regimens.

Keywords : Tuberculosis  Drug Utilization Evaluation  Anti-tubercular Therapy  Multidrug-Resistant Tuberculosis (MDR-TB)  BPaLM Regimen Rational Drug Use  GeneXpert  Pharmacovigilance

References :

1. World Health Organization. "Tuberculosis (TB) Fact Sheet". 14 March 2025.
2. Centers for Disease Control and Prevention. "About Tuberculosis". 27 February 2025.
3. Meulenbeld GJ. "A History of Indian Medical Literature". Groningen: Brill (all volumes, 1999–2002). ISBN 978-9069801247.
4. Sandhu GK. "Tuberculosis: Current situation, challenges and overview of its control in India". J Global Infect Dis. 2011; 3: 143–50.
5. Centers for Disease Control and Prevention. "Clinical Overview of Tuberculosis Disease". https://www.cdc.gov/tb/hcp/clinical-overview/tuberculosis-disease.html
6. Centers for Disease Control and Prevention. "Self-Study Modules on Tuberculosis, Module 1: Transmission     and Pathogenesis             of Tuberculosis". https://www.cdc.gov/tb/media/pdfs/Self_Study_Module_1_Transmission_and_Pathogene sis_of_Tuberculosis.pdf
7. Ahmad F, Rani A, Alam A, Zarin S, Pandey S, Singh H, et al. "Macrophage: A Cell With Many Faces and Functions in Tuberculosis". Front Immunol. 2022; 13: 747799.
8. Hampton MB, Vissers MC, Winterbourn CC. "A single assay for measuring the rates of phagocytosis and bacterial killing by neutrophils". J Leukoc Biol. 1994;55(2):147–52.
9. Rohde K, Yates RM, Purdy GE, Russell DG. "Mycobacterium tuberculosis and the environment within the phagosome". Immunol Rev. 2007; 219: 37–54.
10. Delves PJ, Martin SJ, Burton DR, Roitt IM. "Roitt's Essential Immunology". 11th ed. Malden, MA: Blackwell Publishing; 2006. p. 6–7.
11. Alzayer Z, Al Nasser Y. "Primary Lung Tuberculosis". StatPearls. Treasure Island (FL): StatPearls Publishing; 2025. PMID: 33620814.
12. Silva Miranda M, Breiman A, Allain S, Deknuydt F, Altare F. "The Tuberculous Granuloma: An Unsuccessful Host Defence Mechanism Providing a Safety Shelter for the Bacteria?". J Immunol Res. 2012; 2012: 139127.
13. Crowley LV. "An introduction to human disease: pathology and pathophysiology correlations". 8th ed. Sudbury, MA: Jones and Bartlett; 2010. p. 374.
14. Mayo Clinic. "Tuberculosis - Symptoms and causes". https://www.mayoclinic.org/diseases-conditions/tuberculosis/symptoms-causes/syc-20351250
15. Centers for Disease Control and Prevention. "Clinical and Laboratory Diagnosis for Tuberculosis". https://www.cdc.gov/tb/topic/testing/tbdisease.htm
16. Baron S, editor. "Mycobacterial Infections". Medical Microbiology. 4th ed. Galveston (TX): University of Texas Medical Branch at Galveston; 1996. https://www.ncbi.nlm.nih.gov/books/NBK344401/
17. Bento J, Silva AS, Rodrigues F, Duarte R. "[Diagnostic tools in tuberculosis]". Acta Med Port. 2011; 24 (1):145–54.
18. StatPearls [Internet]. "Tuberculosis". Treasure Island (FL): StatPearls Publishing; 2025.
19. Mayo Clinic. "Tuberculosis-Diagnosis and treatment". https://www.mayoclinic.org/diseases-conditions/tuberculosis/diagnosis-treatment/drc-20351256
20. LLRI.IN. "Tuberculosis Research and Insights". https://share.google/hVOAGTtpLMlNwBEDl
21. Donald PR, Diacon AH. "Para-aminosalicylic acid: the return of an old friend". Lancet Infect Dis. 2015; 15 (9):1091–9.
22. World Health Organization. "The WHO Essential Medicines List (EML): 30th anniversary".
23. Minato Y, Thiede JM, Kordus SL, McKlveen EJ, Turman BJ, Baughn AD. "Mycobacterium tuberculosis folate metabolism and the mechanistic basis for paraaminosalicylic acid susceptibility and resistance". Antimicrob Agents Chemother. 2015; 59 (9):5097–106.
24. Donald PR, Sirgel FA, Botha FJ, et al. "The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis". Am J Respir Crit Care Med. 1997; 156 (3 Pt 1):895–900.
25. Chakraborty S, Rhee KY. "Tuberculosis Drug Development: History and Evolution of the Mechanism-Based Paradigm". Cold Spring Harb Perspect Med. 2015;5 (8): a021147.
26. Ghodousi A, Tagliani E, Karunaratne E, Niemann S, Perera J, Köser CU, Cirillo DM. "Isoniazid Resistance in Mycobacterium tuberculosis Is a Heterogeneous Phenotype Composed of Overlapping MIC Distributions with Different Underlying Resistance Mechanisms". Antimicrob Agents Chemother. 2019; 63 (7): e00092-19.
27. Liu L, Jiang F, Chen L, Zhao B, Dong J, Sun L, et al. "The impact of combined gene mutations in inhA and ahpC genes on high levels of isoniazid resistance amongst katG non-315 in multidrug-resistant tuberculosis isolates from China". Emerg Microbes Infect. 2018; 7 (1):183.
28. Donald PR, van Helden PD. "Antituberculosis Chemotherapy". Basel: Karger Medical and Scientific Publishers; 2011. p. 8.
29. Boshoff HI, Mizrahi V, Barry CE 3rd. "Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I". J Bacteriol. 2002; 184 (8):2167–72.
30. Science Direct. "Ethambutol". https://www.sciencedirect.com/topics/pharmacologytoxicology-and-pharmaceutical-science/ethambutol
31. Sensi P. "History of the development of rifampin". Rev Infect Dis. 1983;5 Suppl 3: S402–6.
32. "Oxford Handbook of Infectious Diseases and Microbiology". Oxford: OUP Oxford; 2009. p. 56.
33. McHugh TD. "Tuberculosis: diagnosis and treatment". Wallingford, Oxfordshire: CAB International; 2011. p. 219.
34. Campbell EA, Korzheva N, Mustaev A, Murakami K, Nair S, Goldfarb A, Darst SA. "Structural mechanism for rifampicin inhibition of bacterial RNA polymerase". Cell. 2001; 104 (6):901–12.
35. McClure WR, Cech CL. "On the mechanism of rifampicin inhibition of RNA synthesis". J Biol Chem. 1978; 253 (24):8949–56.
36. Tanner L, Mashabela GT, Omollo CC, de Wet TJ, Parkinson CJ, Warner DF, Haynes RK, Wiesner L. "Intracellular Accumulation of Novel and Clinically Used TB Drugs Potentiates Intracellular Synergy". Microbiol Spectr. 2021; 9 (2): e00434-21.
37. Carr W, Kurbatova E, Starks A, Goswami N, Allen L, Winston C. "Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of DrugSusceptible Pulmonary Tuberculosis - United States, 2022". MMWR Morb Mortal Wkly Rep. 2022; 71 (8):285–9.
38. "Advances in TB Drug Discovery". https://share.google/jXjQbD5MDejStrbRj
39. Hooper DC. "New uses for new and old quinolones and the challenge of resistance". Clin Infect Dis. 2000; 30 (2):243–54.
40. "Advances in the mechanisms of drug resistance of Mycobacterium tuberculosis". Science Direct. https://share.google/Pwgv23nzhRxTpfvjr
41. World Health Organization. "Tuberculosis: Multidrug-resistant tuberculosis (MDRTB)".  https://www.who.int/news-room/questions-and-answers/item/tuberculosismultidrug-resistant-tuberculosis-(mdr-tb)
42. Houben RMGJ, Dodd PJ. "The Global Burden of Latent Tuberculosis Infection: A Reestimation Using Mathematical Modelling". PLoS Med. 2016; 13(10): e1002152.
43. Press Information Bureau, Government of India. "India's Progress in TB Control". https://www.pib.gov.in/PressReleasePage.aspx?PRID=2052515
44. Fox GJ, Menzies D. "A review of the evidence for using Bedaquiline (TMC207) to treat multi-drug-resistant tuberculosis". Infect Dis Ther. 2013; 2 (2):123–44.
45. Deoghare S. "Bedaquiline: A new drug approved for treatment of multidrugresistant tuberculosis". Indian J Pharmacol. 2013; 45 (5):536–7.
46. Koul A, Vranckx L, Dhar N, Göhlmann HW, Özdemir E, Neefs JM, et al. "Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodeling of bacterial metabolism". Nat Commun. 2014; 5: 3369.
47. Abrahams KA, Batt SM, Gurcha SS, Veerapen N, Bashiri G, Besra GS. "DprE2 is a molecular target of the anti-tubercular nitroimidazole compounds pretomanid and delamanid". Nat Commun. 2023; 14: 3828.
48. Hashemian SMR, Farhadi T, Ganjparvar M. "Linezolid: a review of its properties, function, and use in critical care". Drug Des Devel Ther. 2018; 12: 1759–67.